Amgen (NASDAQ:AMGN) and AstraZeneca (NASDAQ:AZN) announced Friday that their FDA-approved asthma therapy Tezspire reached ...

The companies’ monoclonal antibody met co-primary endpoints in a Phase III trial in patients with chronic rhinosinusitis with ...

Amgen reported a higher quarterly profit on Wednesday, driven by a 24% rise in sales of drugs for high cholesterol and ...

Discover why Amgen is a reliable wealth compounder with strong Q3 results, a promising pipeline, debt reduction, and ...

On Monday, Amgen Inc (AMGN) stock saw a decline, ending the day at $316.91 which represents a decrease of $-2.31 or -0.72% from the prior close of $319.22. The stock opened at $320.58 and touched a ...

AstraZeneca and Amgen's Phase 3 trial data shows Tezspire significantly reduces nasal polyps and congestion in patients with chronic rhinosinusitis with nasal polyps.

Amgen ( AMGN 1.68%), a leader in biotechnology, released its third-quarter 2024 financial results on Oct. 30. The company ...

Amgen (AMGN) and AstraZeneca (AZN) announced top-line results from the Phase 3 WAYPOINT trial in patients with chronic rhinosinusitis with ...

It’s been about one year since Amgen closed its $27.8 billion Horizon Therapeutics buyout and brought the rare disease drug ...

The Amgen STEM Learning Center — located at 260 Ramseyer Hall — opened Oct. 2, offering peer-led tutoring for first- and second-year students in introductory STEM courses. Susan Olesik, dean of ...

These are independent reviews of the products mentioned, but TIME receives a commission when purchases are made through ...

Amgen has begun studying a different weight-loss drug candidate, known as AMG513, but few details were disclosed. The company also announced plans for late-stage testing of experimental ...